Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Brexpiprazole in Pediatric Irritability Associated With Autism Spectrum Disorder
2018-004899-35Phase 3
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in Autism Spectrum Disorder (ASD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Long-term safety and tolerability.
02
Drugs
brexpiprazole
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2018-004899-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004899-35.